Systematic determination of EGFR mutation (m) and immunohistochemistry (IHC) of ALK translocation (t) status in patients (p) with newly non-small cell lung cancer (NSCLC).
2014; Lippincott Williams & Wilkins; Volume: 32; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2014.32.15_suppl.e22112
ISSN1527-7755
AutoresSantiago Ponce Aix, Jon Zugazagoitia, Pilar González‐Márquez, Maria Angeles Torres Nieto, Joan M. Gasent Blesa, Xabier Mielgo-Rubio, Carmen Paz, Rosa Quiben, Juan Luis García Llano, Carmen Perez Agua, Pilar Resano, Julia Calzas, Lourdes García, Victor M. Diaz Muñoz, L. Iglesias, Juan Antonio Vargas, Rosa María García Martín, H. Cortés-Funes, José Luis Rodríguez‐Peralto, Ana Belén Enguita Valls,
Tópico(s)Lung Cancer Research Studies
Resumoe22112 Background: Detection of EGFR m in p with NSCLC is done in a routine way. Given the data published on ALK positive p detection is crucial for therapeutic decision making. ALK t should be performed using FISH break apart probes for selecting p but probably is not enough quick for clinical wide use. Based on promising results IHC assay may be used as screening. We implemented a systematic determination of EGFR m and ALK t status to asses feasibility and accuracy in a clinical setting. Methods: We have tested all p with newly diagnosed NSCLC (non squamous or squamous with a light smoking history) from 12 centers. All samples were send to H. 12 de Octubre (June -December 2013). The objective was to evaluate the accuracy of EGFR m testing (TheraScreen/Cobas test) and ALK t testing. We performed IHC, as screening, using Ventana D5F3 mouse monoclonal antibody. P with positive IHC were checked using Abbot Vysis Break Apart. Results: 366 p were tested for EGFR/ALK simultaneously. 109 (29.78 %) were women and 257 (70.21 %) men. 361 (98.63 %) caucasian and 5 (1.36 %) asiatics. 246 (67.21 %) adenocarcinoma, 60 (16.39 %) non other specify, 35 (9.56 %) squamous, 17 (4.64 %) large cell carcinoma, 6 (1.63 %) adenosquamous and 2 (0.54 %) large cell carcinoma with neuroendocrine differentiation. 125 (34.15%) former smokers, 100 (27.32 %) current smokers, 97 (26.5 %) unknown and 44 (12.02 %) never smokers. The tumor sample was paraffin embedded (89.61 %) and cytology (10.38 %). We performed successfully EGFR test in 97.27 % and IHC in 95.91 %. The median time to results was 5.8 days. 29 p with EGFR m (7.92) were found: del 19 (58.62%) 21 L858R (20.68%) exon 18 (6.88%) 20 ins (10.34%) and one double mutation (18-G719X plus 20-S7681).15 p with IHC ALK t positive (4.09%) were found; all of them were confirmed by FISH with full concordance. Most of the ALK t patients were adenocarcinoma (86.66%) but 1 adenosquamous and 1 squamous. Conclusions: Systematic determination of EGFR m. and ALK t. in several public centers is feasible offering a good time to result and good performance. In our experience IHC should be done, instead FISH, in all non squamous NSCLC patients and in those squamous with light smoking history.
Referência(s)